Brian Joseph Kieser - 10 Nov 2026 Form 4 Insider Report for NEXGEL, INC. (NXGL)

Reporting relationship: Interim CEO, Director, 10%+ Owner
Issuer ticker: NXGL
Reported as of: 10 Nov 2026
Net transaction value: +$732,688
SEC form: 4
Accepted by SEC: 13 Nov 2026, 21:59:13 UTC
Prior SEC filing: 18 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Brian Joseph Kieser

Filing notes and source

Key filing fact

Brian Joseph Kieser filed Form 4 for NEXGEL, INC. (NXGL) on 13 Nov 2026.

Key facts

This page summarizes Brian Joseph Kieser's Form 4 filing for NEXGEL, INC. (NXGL).
10 reported transactions and 9 derivative rows are listed below.
Accepted by SEC: 13 Nov 2026, 21:59.

Change

Previous filing in this sequence was filed on 18 May 2026.
Current net transaction value: +$732,688.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002133654 Primary reporting owner

Kieser Brian Joseph

Relationship: Interim CEO, Director, 10%+ Owner
Address: C/O NEXGEL, INC. 2150 CABOT BLVD, WEST,, SUITE B, LANGHORNE
Signature: /s/ Brian Joseph Kieser
Signature date: 13 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NXGL transaction

Common Stock

Purchase

Transaction value: $732,688
Shares: +133,216
Change %
Price: $5.50
Shares after: 133,216
Date: 10 Nov 2026
Ownership: By Sequence LifeScience, Inc.
Footnotes: F1, F2, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NXGL transaction Derivative

Warrant to Purchase Common Stock (the "PIPE Warrant")

Purchase

Transaction value
Shares: +133,216
Change %
Price: $0.000000^*
Shares after: 133,216
Date: 10 Nov 2026
Ownership: By Sequence LifeScience, Inc.
Underlying class: Common Stock
Underlying amount: 133,216
Exercise price: $10.00
Footnotes: F1, F5

NXGL transaction Derivative

Convertible Promissory Note (before amendment)

Disposed to Issuer

Transaction value
Shares: +83,334
Change %
Price
Shares after: 0
Date: 10 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 83,334
Exercise price: $12.00
Footnotes: F3

NXGL transaction Derivative

Convertible Promissory Note (as amended)

Award

Transaction value
Shares: +181,819
Change %
Price
Shares after: 181,819
Date: 10 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 181,819
Exercise price: $5.50
Footnotes: F3, F4

NXGL transaction Derivative

Warrant to Purchase Common Stock

Disposed to Issuer

Transaction value
Shares: +41,667
Change %
Price
Shares after: 0
Date: 10 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 41,667
Exercise price: $16.00
Footnotes: F3

NXGL transaction Derivative

Existing Warrant (as amended)

Award

Transaction value
Shares: +41,667
Change %
Price
Shares after: 41,667
Date: 10 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 41,667
Exercise price: $13.00
Footnotes: F3

NXGL transaction Derivative

Convertible Promissory Note (before amendment)

Disposed to Issuer

Transaction value
Shares: +458,334
Change %
Price
Shares after: 0
Date: 10 Nov 2026
Ownership: By Sequence LifeScience, Inc.
Underlying class: Common Stock
Underlying amount: 458,334
Exercise price: $12.00
Footnotes: F3, F5

NXGL transaction Derivative

Convertible Promissory Note (as amended)

Award

Transaction value
Shares: +1,000,000
Change %
Price
Shares after: 1,000,000
Date: 10 Nov 2026
Ownership: By Sequence LifeScience, Inc.
Underlying class: Common Stock
Underlying amount: 1,000,000
Exercise price: $5.50
Footnotes: F3, F4, F5

NXGL transaction Derivative

Existing Warrant (before amendment)

Disposed to Issuer

Transaction value
Shares: +229,167
Change %
Price
Shares after: 0
Date: 10 Nov 2026
Ownership: By Sequence LifeScience, Inc.
Underlying class: Common Stock
Underlying amount: 229,167
Exercise price: $16.00
Footnotes: F3, F5

NXGL transaction Derivative

Existing Warrant (as amended)

Award

Transaction value
Shares: +229,167
Change %
Price
Shares after: 229,167
Date: 10 Nov 2026
Ownership: By Sequence LifeScience, Inc.
Underlying class: Common Stock
Underlying amount: 229,167
Exercise price: $13.00
Footnotes: F3, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Reflects the purchase by Sequence LifeScience, Inc. ("Sequence") on November 10, 2026 of 133,216 units from the Issuer, each unit consisting of one share of Common Stock and a warrant to purchase one share of Common Stock (the "PIPE Warrant"), at $5.50 per unit, in a private placement under a Securities Purchase Agreement. No separate consideration was paid for the PIPE Warrant. The closing occurred on November 10, 2026. The PIPE Warrant has an original issue date of November 10, 2026, is exercisable for cash at $10.00 per share, and expires on the fifth anniversary of its original issue date. The Issuer has waived the beneficial-ownership limitation that would otherwise apply to these securities.

Footnote F2

Share and underlying-share amounts reflect the 1-for-20 reverse stock split of the Issuer's common stock effective October 12, 2026.

Footnote F3

On November 10, 2026, the Reporting Person and Sequence entered into Note Amendment and Conversion Agreements with the Issuer that, among other things, reduced the conversion price of each Convertible Promissory Note from $12.00 to $5.50 per share and the exercise price of each Existing Warrant from $16.00 to $13.00 per share. The amendments are reported as the disposition of the original derivative security and the acquisition of the amended derivative security. The original securities are treated as disposed of solely for purposes of this Form 4 reporting; they were amended and remain outstanding as amended. The transactions were approved in advance by the Issuer's Board of Directors on November 10, 2026 for purposes of Rule 16b-3(d) and (e). Share amounts reflect the 1-for-20 reverse stock split effective October 12, 2026. The Note and Existing Warrant held directly were issued on May 11, 2026, and those held by Sequence were issued on April 17, 2026.

Footnote F4

The conversion price is subject to reset on the first anniversary of issuance and at maturity. The Note converts at the Issuer's closing of the contemplated merger or earlier at the holder's election, subject to the Exchange Cap.

Footnote F5

The securities are held of record by Sequence. The Reporting Person is the indirect sole owner of Sequence and may be deemed to have voting and investment power over the securities held by Sequence. The Reporting Person disclaims beneficial ownership of the securities held by Sequence except to the extent of his pecuniary interest therein.